Preformulation of a liquid dosage formulation of captopril for pediatric use: drug-excipient compatibility and stability studies
DOI:
https://doi.org/10.1590/s2175-97902019000218015Keywords:
Pediatric Formulation, Captopril/ pharmacokinetics, Thermal Analysis, Degradation Kinetics, Drug Stability, Drug Compounding/ utilization, Drug Utilization, Excipients/ pharmacokinetics, Dosage Forms, Drug Dosage Calculations, Kinetics, Enzyme Stability/drug effectsAbstract
Currently, medications used in children are typically modified from pharmaceutical dosage forms designed for adults. Captopril is widely adapted to liquid formulations for use in hospitals. Its stability in the aqueous medium is reduced since it undergoes oxidation producing captopril disulfide (its main metabolite). The aim of this formulation study was to suggest favorable conditions for the development of a stable captopril formulation. The compatibility between the drug and excipients was evaluated by differential scanning calorimetry analysis (DSC). For studies in solution, different formulations were prepared according to a factorial design varying EDTA concentration, water purity and pH. The resultant formulations were stored at 60°C and analyzed over a twelve-day period using HPLC. The DSC curves obtained suggested, although not conclusive to elucidation, interactions of captopril with citric acid and sucralose. The stability study of these solutions revealed that the variables significantly influenced captopril content, which degraded at zero order kinetics and rates differing by a factor of up to 7 times, where pH proved the most influential factor. Interactions between variables were observed. Therefore, development of a stable captopril formulation is feasible provided EDTA and a buffering agent is used at suitable concentrations (0.08% and pH 3.85).
Downloads
Downloads
Published
Issue
Section
License
Copyright (c) 2019 Brazilian Journal of Pharmaceutical Sciences

This work is licensed under a Creative Commons Attribution 4.0 International License.
All content of the journal, except where identified, is licensed under a Creative Commons attribution-type BY.
The on-line journal has open and free access.